Real-World CML treatment under the microscope: chart review aims to fill knowledge gaps

NCT ID NCT00816114

First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 20 times

Summary

This study reviews the medical charts of up to 3,000 people with chronic myeloid leukemia (CML) who received standard tyrosine kinase inhibitor drugs (like imatinib, dasatinib, or nilotinib) outside of a clinical trial. The goal is to learn how these patients respond to treatment in real-world settings, including effects of dose changes, treatment breaks, and pregnancy during therapy. No new treatments are given; researchers simply collect existing information from patient records.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.